The PI3K-AKT1-PTEN signaling pathway has an important role in hormone receptor positive, HER2 negative (HR + /HER-) breast cancer progression and therapy resistance. Here, the author report the efficacy and safety of afuresertib, a pan AKT inhibitor, plus fulvestrant (hormone therapy) in patients with pretreated, HR-positive, HER2- negative advance breast cancer.
- Pin Zhang
- Tao Sun
- Binghe Xu